---
title: "Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283873730.md"
description: "Jason McCarthy from Maxim Group has maintained a Buy rating on Vyome Holdings with a price target of $15.00. He cites strong Phase 2 data for VT-1953, a topical gel for malignant fungating wounds, and the upcoming pivotal Phase 3 trial as key factors. The drug addresses a significant market opportunity exceeding $2B, and Vyome's financial position supports operations into mid-2027. McCarthy views the shares as undervalued given the program's de-risked outlook and upcoming catalysts."
datetime: "2026-04-23T17:35:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283873730.md)
  - [en](https://longbridge.com/en/news/283873730.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283873730.md)
---

# Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Vyome Holdings, with a price target of $15.00.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Jason McCarthy has given his Buy rating due to a combination of factors tied to Vyome’s lead program and financial position. He highlights that VT-1953, a topical gel for malignant fungating wounds, has generated robust Phase 2 data showing statistically significant improvement in malodor, pain, and quality of life versus vehicle, with no treatment-related safety issues, which strengthens the case for the drug’s clinical profile.

He also notes that the company is preparing to initiate a pivotal Phase 3 trial in a rare, severely underserved indication that currently lacks approved therapies, implying a sizable commercial opportunity exceeding $2B. In addition, Vyome’s existing cash balance, supplemented by available ATM capacity, appears sufficient to fund operations into mid-2027 and advance VT-1953 through key inflection points, leading him to view the shares as undervalued relative to the program’s de-risked outlook and upcoming catalysts.

McCarthy covers the Healthcare sector, focusing on stocks such as Aprea Therapeutics, Moleculin Biotech, and Plus Therapeutics. According to TipRanks, McCarthy has an average return of \-14.2% and a 32.73% success rate on recommended stocks.

### Related Stocks

- [HIND.US](https://longbridge.com/en/quote/HIND.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [APRE.US](https://longbridge.com/en/quote/APRE.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [PSTV.US](https://longbridge.com/en/quote/PSTV.US.md)

## Related News & Research

- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)